Briefing
Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer
In a prospective Hong Kong screening study of 20,174 asymptomatic participants, plasma EBV DNA identified 34 nasopharyngeal carcinomas, with 97.1% sensitivity, 98.6% specificity, and a higher fraction of stage I–II disease than a historical cohort (71% vs 20%).
- Design: Evidence level 2
- Assay: Not named in the abstract